344 related articles for article (PubMed ID: 37480137)
1. Novel target and treatment agents for natural killer/T-cell lymphoma.
Tian XP; Cao Y; Cai J; Zhang YC; Zou QH; Wang JN; Fang Y; Wang JH; Guo SB; Cai QQ
J Hematol Oncol; 2023 Jul; 16(1):78. PubMed ID: 37480137
[TBL] [Abstract][Full Text] [Related]
2. Updating targets for natural killer/T-cell lymphoma immunotherapy.
Xue W; Zhang M
Cancer Biol Med; 2021 Feb; 18(1):52-62. PubMed ID: 33628584
[TBL] [Abstract][Full Text] [Related]
3. Analysis of latent T-cell epitopes in Epstein-Barr virus isolated from extranodal nasal-type natural killer/T-cell lymphoma in Taiwanese population.
Chou CC; Tsao CF; Liao CK; You HL; Wang MC; Huang WT
Exp Mol Pathol; 2021 Feb; 118():104577. PubMed ID: 33242451
[TBL] [Abstract][Full Text] [Related]
4. Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type.
Lin N; Ku W; Song Y; Zhu J; Lu Z
Oncologist; 2019 Sep; 24(9):e905-e913. PubMed ID: 30940744
[TBL] [Abstract][Full Text] [Related]
5. Advances and challenges of immunotherapies in NK/T cell lymphomas.
He L; Chen N; Dai L; Peng X
iScience; 2023 Nov; 26(11):108192. PubMed ID: 38026157
[TBL] [Abstract][Full Text] [Related]
6. T-cell dysfunction in natural killer/T-cell lymphoma.
Feng X; Meng M; Li H; Gao Y; Song W; Di R; Li Z; Zhang X; Zhang M
Oncoimmunology; 2023; 12(1):2212532. PubMed ID: 37250921
[TBL] [Abstract][Full Text] [Related]
7. Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma.
Xiong J; Cui BW; Wang N; Dai YT; Zhang H; Wang CF; Zhong HJ; Cheng S; Ou-Yang BS; Hu Y; Zhang X; Xu B; Qian WB; Tao R; Yan F; Hu JD; Hou M; Ma XJ; Wang X; Liu YH; Zhu ZM; Huang XB; Liu L; Wu CY; Huang L; Shen YF; Huang RB; Xu JY; Wang C; Wu DP; Yu L; Li JF; Xu PP; Wang L; Huang JY; Chen SJ; Zhao WL
Cancer Cell; 2020 Mar; 37(3):403-419.e6. PubMed ID: 32183952
[TBL] [Abstract][Full Text] [Related]
8. [Advances of treatment for nature killer/T-cell lymphoma].
Wang H; Pan XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1453-8. PubMed ID: 25338606
[TBL] [Abstract][Full Text] [Related]
9. Review on natural killer/T-cell lymphoma.
He X; Gao Y; Li Z; Huang H
Hematol Oncol; 2023 Apr; 41(2):221-229. PubMed ID: 34731509
[TBL] [Abstract][Full Text] [Related]
10. Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management.
Tse E; Fox CP; Glover A; Yoon SE; Kim WS; Kwong YL
Semin Hematol; 2022 Oct; 59(4):198-209. PubMed ID: 36805888
[TBL] [Abstract][Full Text] [Related]
11. Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma.
Peng RJ; Han BW; Cai QQ; Zuo XY; Xia T; Chen JR; Feng LN; Lim JQ; Chen SW; Zeng MS; Guo YM; Li B; Xia XJ; Xia Y; Laurensia Y; Chia BKH; Huang HQ; Young KH; Lim ST; Ong CK; Zeng YX; Bei JX
Leukemia; 2019 Jun; 33(6):1451-1462. PubMed ID: 30546078
[TBL] [Abstract][Full Text] [Related]
12. Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab.
Qing M; Zhou T; Perova T; Abraham Y; Sweeney C; Krevvata M; Zhang X; Qi M; Gao G; Kim TM; Yao M; Cho SG; Eom HS; Lim ST; Yeh SP; Kwong YL; Yoon DH; Kim JS; Kim WS; Zhou L; Attar R; Verona RI
Ann Hematol; 2024 Jun; 103(6):1989-2001. PubMed ID: 38233570
[TBL] [Abstract][Full Text] [Related]
13. CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase.
Yang J; Li P; Piao Y; Liu X; Wei L; Sang W; Zhang L; Wang L
Front Immunol; 2022; 13():829366. PubMed ID: 35371002
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report.
Lai J; Xu P; Jiang X; Zhou S; Liu A
BMC Cancer; 2017 Jul; 17(1):507. PubMed ID: 28754096
[TBL] [Abstract][Full Text] [Related]
15. Long-term eradication of extranodal natural killer/T-cell lymphoma, nasal type, by induced pluripotent stem cell-derived Epstein-Barr virus-specific rejuvenated T cells
Ando M; Ando J; Yamazaki S; Ishii M; Sakiyama Y; Harada S; Honda T; Yamaguchi T; Nojima M; Ohshima K; Nakauchi H; Komatsu N
Haematologica; 2020 Mar; 105(3):796-807. PubMed ID: 31296577
[TBL] [Abstract][Full Text] [Related]
16. SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential.
Xiong J; Wang N; Zhong HJ; Cui BW; Cheng S; Sun R; Chen JY; Xu PP; Cai G; Wang L; Sun XJ; Huang JY; Zhao WL
EBioMedicine; 2021 Oct; 72():103614. PubMed ID: 34628354
[TBL] [Abstract][Full Text] [Related]
17. Full-spectral genome analysis of natural killer/T cell lymphoma highlights impacts of genome instability in driving its progression.
Chen Z; Huang H; Hong H; Huang H; Weng H; Yu L; Xiao J; Wang Z; Fang X; Yao Y; Yue JX; Lin T
Genome Med; 2024 Apr; 16(1):48. PubMed ID: 38566223
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the humoral immune response to the EBV proteome in extranodal NK/T-cell lymphoma.
Liu Z; Sarathkumara YD; Chan JKC; Kwong YL; Lam TH; Ip DKM; Chiu BC; Xu J; Su YC; Proietti C; Cooper MM; Yu KJ; Bassig B; Liang R; Hu W; Ji BT; Coghill AE; Pfeiffer RM; Hildesheim A; Rothman N; Doolan DL; Lan Q
Sci Rep; 2021 Dec; 11(1):23664. PubMed ID: 34880297
[TBL] [Abstract][Full Text] [Related]
20. Chemorefractory extranodal nasal-type natural-killer/T-cell lymphoma with great response to pembrolizumab in a young patient: a case report.
Adabifirouzjaei F; Khazai B; Azami G; Shoja-E-Razavi G
J Med Case Rep; 2021 Oct; 15(1):539. PubMed ID: 34702349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
